![(E)-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)but-2-en-1-one](https://veeprho.com/wp-content/uploads/2022/09/E-1-3-trifluoromethyl-5-6-dihydro-1-2-4-triazolo-4-3-a-pyrazin-7-8H-yl-4-2-4-5-trifluorophenyl-but-2-en-1-one.png)
(E)-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)but-2-en-1-one
It is one of impurity present in Sitagliptin. Sitagliptin is a dipeptidyl peptidase inhibitor, which increases levels of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide that decreased levels of glucagon. Reduced inhibition of incretins increases insulin synthesis and decreases glucagon release in a manner dependent on glucose concentrations. These effects lead to an overall increase in blood glucose control which is demonstrated by reduced glycosylated hemoglobin, which is used for the management of type 2 diabetes mellitus.
Additional information on (E)-1-(3-(trifluoromethyl)-5 | 6-dihydro-[1 | 2 | 4]triazolo[4 | 3-a]pyrazin-7(8H)-yl)-4-(2 | 4 | 5-trifluorophenyl)but-2-en-1-one
VE009354
N/A
C16H12F6N4O
390.28 g/mol
Sitagliptin
(E)-1-(3-(trifluoromethyl)-5, 6-dihydro-[1, 2, 4]triazolo[4, 3-a]pyrazin-7(8H)-yl)-4-(2, 4, 5-trifluorophenyl)but-2-en-1-one
N/A
Gallwitz, B. (2007). Review of sitagliptin phosphate: a novel treatment for type 2 diabetes. Vascular Health and Risk Management, 3(2), 203–210. https://doi.org/10.2147/vhrm.2007.3.2.203
In-stock
